Analysts Set ProQR Therapeutics N.V. (NASDAQ:PRQR) Price Target at $7.25

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $7.25.

A number of brokerages have weighed in on PRQR. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a research report on Friday, March 13th. Wall Street Zen lowered ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Weiss Ratings lowered ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. Chardan Capital reaffirmed a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a research report on Thursday, April 9th. Finally, Oppenheimer started coverage on shares of ProQR Therapeutics in a research report on Thursday, March 12th. They set an “outperform” rating and a $9.00 price target for the company.

Institutional Investors Weigh In On ProQR Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Aberdeen Group plc increased its position in shares of ProQR Therapeutics by 24.2% during the 3rd quarter. Aberdeen Group plc now owns 2,298,823 shares of the biopharmaceutical company’s stock valued at $4,896,000 after purchasing an additional 448,475 shares during the last quarter. Privium Fund Management B.V. increased its position in shares of ProQR Therapeutics by 7.2% during the 4th quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company’s stock valued at $10,823,000 after purchasing an additional 359,475 shares during the last quarter. Quadrature Capital Ltd increased its position in shares of ProQR Therapeutics by 188.4% during the 4th quarter. Quadrature Capital Ltd now owns 104,231 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 68,091 shares during the last quarter. Geode Capital Management LLC increased its position in shares of ProQR Therapeutics by 73.9% during the 4th quarter. Geode Capital Management LLC now owns 84,909 shares of the biopharmaceutical company’s stock valued at $172,000 after purchasing an additional 36,087 shares during the last quarter. Finally, Persistent Asset Partners Ltd increased its position in shares of ProQR Therapeutics by 24.5% during the 4th quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock valued at $91,000 after purchasing an additional 8,874 shares during the last quarter. Hedge funds and other institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Stock Performance

Shares of NASDAQ:PRQR opened at $1.56 on Thursday. ProQR Therapeutics has a fifty-two week low of $1.33 and a fifty-two week high of $3.10. The business has a 50-day simple moving average of $1.66 and a two-hundred day simple moving average of $1.81. The firm has a market cap of $164.36 million, a price-to-earnings ratio of -3.12 and a beta of 0.08.

ProQR Therapeutics (NASDAQ:PRQR) last issued its earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.15). ProQR Therapeutics had a negative return on equity of 84.87% and a negative net margin of 331.33%.The business had revenue of $2.35 million during the quarter, compared to analyst estimates of $5.19 million. As a group, research analysts predict that ProQR Therapeutics will post -0.57 earnings per share for the current year.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.